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Abstract
We performed a single-institution retrospective analysis of 137 patients with muscle-invasive 
urothelial carcinoma who underwent neoadjuvant chemotherapy and radical cystectomy to assess 
the prognostic significance of carcinoma in situ (CIS). The pathologic complete response rates 
were significantly decreased for patients with CIS identified on transurethral resection of the 
bladder tumor before treatment. The long-term follow-up data from patients with isolated CIS at 
cystectomy revealed prolonged progression-free and overall survival.
Background—Carcinoma in situ (CIS) is a poor prognostic finding in urothelial carcinoma. 
However, its significance in muscle-invasive urothelial carcinoma (MIUC) treated with 
neoadjuvant chemotherapy (NAC) is uncertain. We assessed the effect of CIS found in 
pretreatment transurethral resection of bladder tumor (TURBT) biopsies on the pathologic and 
clinical outcomes.
Materials and Methods—Subjects with MIUC treated with NAC before cystectomy were 
identified. The pathologic complete response (pCR) rates stratified by TURBT CIS status were 
compared. The secondary analyses included tumor response, progression-free survival (PFS), 
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overall survival (OS), and an exploratory post hoc analysis of patients with pathologic CIS only 
(pTisN0) at cystectomy.
Results—A total of 137 patients with MIUC were identified. TURBT CIS was noted in 30.7% of 
the patients. The absence of TURBT CIS was associated with a significantly increased pCR rate 
(23.2% vs. 9.5%; odds ratio, 4.08; 95% confidence interval, 1.19–13.98; P = .025). Stage pTisN0 
disease was observed in 19.0% of the TURBT CIS patients. TURBT CIS status did not 
significantly affect the PFS or OS outcomes. Post hoc analysis of the pTisN0 patients revealed 
prolonged median PFS (104.5 vs. 139.9 months; P = .055) and OS (104.5 vs. 152.3 months; P = .
091) outcomes similar to those for the pCR patients.
Conclusion—The absence of CIS on pretreatment TURBT in patients with MIUC undergoing 
NAC was associated with increased pCR rates, with no observed differences in PFS or OS. 
Isolated CIS at cystectomy was frequently observed, with lengthy PFS and OS durations similar to 
those for pCR patients. Further studies aimed at understanding the biology and clinical effect of 
CIS in MIUC are warranted.
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Introduction
Urothelial carcinoma (UC) of the bladder is a common cancer, with > 76, 000 new cases 
diagnosed and 16,000 deaths annually in the United States.1 Worldwide, an estimated 
450,000 new cases and 165,000 deaths occur annually.2 In muscle-invasive UC (MIUC), 
radical cystectomy remains a standard treatment approach with significant quality of life 
effects. Given the substantial morbidity from surgical intervention and metastatic relapse 
rates approaching 50%, the identification of clinical, pathologic, and molecular factors that 
affect patient outcomes is critical to the success of personalized patient care.3
When observed, the presence of carcinoma in situ (CIS) has been associated with an 
aggressive, initially immunotherapy responsive phenotype. CIS has been shown to have a 
54% to 83% risk of progression to MIUC if left untreated.4,5 Additionally, extravesical 
involvement of UC is common with CIS and carries a worse prognosis.6,7 Aggressive 
intravesical therapy after the initial resection of non–muscle invasive UC (NMIUC) or 
cystectomy in patients developing relapse after adequate intravesical therapy has typically 
been recommended.8 Uncertainty regarding the distinct mechanisms responsible for the 
improved response rates to local immunotherapy in patients with CIS compared with those 
with high-grade papillary NMIUC (< pT2) underscores the need for improved understanding 
of the underlying pathobiology of CIS.9,10
In patients with UC, CIS can be present as an isolated finding or simultaneously in 
association with more invasive tumors within the bladder and upper urinary tract. A study by 
Shariat et al11 noted significantly increased disease recurrence when CIS was identified on 
cystectomy specimens performed for NMIBC. Another study by Gupta et al12 revealed 
increased recurrence rates and decreased cancer-specific survival (CSS) in patients with 
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NMIBC treated with cystectomy if CIS had been identified on precystectomy transurethral 
resection of bladder tumor (TURBT) samples.12 A meta-analysis by Sylvester et al13 also 
showed that the presence of concurrent CIS within stage Ta or T1 TURBT specimens 
correlated with significantly increased risks of disease recurrence and progression. Two large 
retrospective studies attempted to evaluate whether CIS has prognostic significance 
specifically in patients with MIUC. Yafi et al14 found that CIS found on TURBT in patients 
with MIUC led to statistically significant upstaging at cystectomy; however, no significant 
differences in progression-free survival (PFS), CSS, or overall survival (OS) were observed. 
Nuhn et al15 evaluated MIUC cystectomy specimens for the presence of CIS and found no 
associated differences in PFS or CSS.
Level 1 evidence from randomized clinical trials demonstrated significant improvements in 
OS with the use of neoadjuvant cisplatin-based combination chemotherapy before 
cystectomy for eligible patients with MIUC.16,17 Furthermore, the neoadjuvant approach 
represents an attractive setting for drug development, because multiple studies have 
demonstrated an association between the pathologic response and longer term survival 
outcomes.17–20 In general, agreement exists that a reduction in stage to a non–muscle-
invasive stage (< pT2N0) confers more favorable outcomes. It is less clear whether a 
pathologic complete response (pCR), defined as no evidence of any tumor of any stage 
(pT0N0), is necessary for patient benefit compared with simply a reduction to a non–
muscle-invasive stage. Because clinical trials now commonly use pCR as a primary endpoint 
for neoadjuvant MIUC trials, a thorough understanding of the baseline patient factors with 
an effect on pCR rates is critical. In the only study to analyze the effect of TURBT CIS on 
the cystectomy pathologic response in MIUC patients who received neoadjuvant 
chemotherapy (NAC), Parker et al21 reported inferior pCR rates at cystectomy in association 
with TURBT CIS; however, no effect on survival outcomes was observed. We present the 
results from our large single-institution retrospective analysis evaluating the pathologic and 
prognostic significance of pretreatment TURBT CIS in patients with MIUC treated with 
NAC followed by cystectomy.
Materials and Methods
Study Cohort
The study subjects were identified from the urology and medical oncology department 
clinical databases of Indiana University Simon Cancer Center (IUSCC). The eligibility 
criteria included patients of any age with nonmetastatic UC who were documented to have 
received NAC and whose pathologic reports were available for both prechemotherapy 
TURBT (or staging biopsy) and post-chemotherapy cystectomy. Patients with clinical lymph 
node-positive disease found on imaging studies were included as long as NAC and 
cystectomy had been performed with curative intent. Subjects with components of non–
small-cell variant histologic features were allowed; however, subjects with pure 
nonurothelial histologic features found on TURBT were excluded. Subjects with NMIUC 
and those with any component of small cell or neuroendocrine features on TURBT were 
excluded. The institutional review board of the IUSCC approved the present study.
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Pathologic Staging and Response Evaluation
All cystectomies were performed at the IUSCC (Indianapolis, IN). All TURBTs and 
cystectomy pathologic specimens obtained at IUSCC were reviewed by expert genitourinary 
pathologists. The slides from TURBTs performed at outside institutions were not uniformly 
reviewed again, and staging was established by a review of the outside pathology reports. 
Pathologic staging was performed in accordance with the American Joint Committee on 
Cancer TNM system for UC of the bladder. A pCR was defined by a finding of T0N0 at 
cystectomy.
Clinical Data Evaluation
The available clinical and demographic information was recorded for all study subjects and 
included the following: age at TURBT, gender, race, Eastern Cooperative Oncology Group 
performance status, Karnofsky performance status, baseline laboratory values (creatinine, 
white blood cell count, hemoglobin, platelet count), TURBT date, clinical stage (including 
TURBT pathologic findings and other staging diagnostics), presence of variant histologic 
features on TURBT (types and percentages, if reported), the presence of CIS on TURBT, 
NAC regimen, cycles of NAC completed, cystectomy date, pathologic stage, date of 
progression, date of death, and date of the last follow-up visit. The data were tabulated into a 
clinical database for further statistical analyses (Figure 1). All primary information was 
gathered from the IUSCC and associated hospital electronic medical record systems.
Data Verification and Missing Data Methods
The clinical information, including the pathologic reports and stage, was verified by all 
investigators for accuracy. For the TURBT cases from outside institutions, which were 
reviewed by IUSCC pathologists, the IUSCC pathology review date was used as the TURBT 
date if the original TURBT date was not available from the outside institution pathology 
report. If the original TURBT date was supplied, the original TURBT date was used in all 
analyses.
Survival Evaluation
PFS was calculated as the duration between the TURBT date and the occurrence of either 
death from any cause or documented UC recurrence radiographically or clinically. OS was 
calculated as the duration between the TURBT date and death from any cause. For both PFS 
and OS analyses, patients lost to follow-up were censored at their last known follow-up date.
Statistical Analysis
The primary outcome of interest in our analysis was the pCR rate. We aimed to test the 
experimental hypothesis that the finding of CIS in TURBT samples from MIUC patients 
would be associated with lower pCR rates after NAC. All baseline clinical variables for 
which data were complete (age at TURBT, gender, race, clinical stage, NAC regimen, 
presence of variant histologic features, CIS on TURBT) were evaluated by logistic 
regression analyses for associations with the pCR rate, with the significance level set at P < .
05. Continuous variables (ie, age at TURBT) were dichotomized according to the median 
values. Odds ratios (ORs) and 95% confidence intervals (CIs) were computed for all 
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variables analyzed. The secondary outcomes included comparisons of PFS and OS 
according to TURBT CIS status. Kaplan-Meier curves were calculated and log-rank 
analyses used to compare the PFS and OS according to TURBT CIS status and according to 
pathologic pTis status. χ2 Tests and Student t tests were used to assess the differences in 
baseline demographic variables between patients with and without CIS on TURBT. χ2 Tests 
were used in exploratory analyses to identify the baseline factors predictive of pTisN0 status. 
All analyses were performed using SPSS Statistics, version 22.
Results
Patient Population
After database review, 152 potential subjects were identified. Of the 152 potential subjects, 6 
with stage T1 NMIUC and 9 with small cell carcinoma or neuroendocrine features were 
excluded, leaving a final study data set of 137 subjects (Figure 2). The study data set was 
divided into 2 cohorts, with 42 subjects with CIS found on TURBT (30.7%) and 95 subjects 
without CIS found on TURBT. The patients had documented follow-up data available for an 
average of 25.4 months (range, 0–264 months).
The patient demographics are listed in Table 1. The study population was a largely white 
male population, with a mean age of 61.1 years (median, 62.0 years). Most patients had 
clinical stage T2N0, and 40 patients (29.2%) had clinical lymph node involvement. 
Cisplatin-based NAC was used in 113 patients (82.5%). The presence of variant histologic 
features was noted in 46 patients (33.6%). Subjects with CIS found on TURBT were more 
frequently women, had a greater incidence of clinical stage T2N0 disease, had a lower 
incidence of clinical lymph node-positive disease, and were more frequently treated with 
cisplatin NAC. However, none of these differences were statistically significant.
NAC Tumor Response
The pCR rate at cystectomy was lower in patients with CIS found on TURBT (9.5% vs. 
23.2%; P = .07; Table 2). Furthermore, a significantly greater frequency of pTisN0M0 stage 
was observed at cystectomy in patients with CIS found on TURBT (19.0% vs. 3.2%; P < .
01). The rates of < pT2N0M0, pN+, and pM1 disease were similar between the 2 groups.
Binary and Multinomial Logistic Regression Analyses
Complete data were available for age, TURBT CIS status, variant histologic status, race, 
gender, pre-NAC clinical stage, and cisplatin NAC status. On binary logistic regression 
analysis of these variables, age ≤ 62 years (OR, 2.76; 95% CI, 1.06–7.10; P = .035) and 
nonwhite race (OR, 6.37; 95% CI, 1.58–25.71; P = .009) were statistically associated with 
increased pCR rates. The absence of CIS on TURBT approached a statistical association 
with increased pCR rates (OR, 2.86; 95% CI, 0.92–8.91; P = .069). On multinomial logistic 
regression analysis, the absence of CIS on TURBT (OR, 4.08; 95% CI, 1.19–13.98; P = .
025) and nonwhite race (OR, 6.05; 95% CI, 1.17–31.14; P = .031) were significantly 
associated with increased pCR rates. Both age ≤ 62 years and pre-NAC clinical stage T2N0 
showed a trend toward statistical significance. The full results are summarized in Table 3.
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Survival Analyses
The mean follow-up duration for subjects with and without CIS found on TURBT was 31.0 
months (range, 0–204 months) and 22.4 months (range, 0–264 months). The median PFS for 
the entire cohort was 20.0 months (95% CI, 10.1–29.8 months), with a median OS of 33.8 
months (95% CI, 17.3–50.4 months). The median PFS (27.6 vs. 18.2 months) and OS (47.6 
vs. 29.4 months) were both increased for patients with CIS present on TURBT; however, 
neither result was statistically significant on log-rank testing (P = .67 for PFS and P = .82 for 
OS). Both PFS and OS stratified by TURBT CIS status are depicted in Figure 3. Given the 
high percentage of patients with pTisN0M0 disease at cystectomy in patients with CIS found 
on pre-NAC TURBT, an exploratory analysis of PFS and OS between the pCR and 
pTisN0M0 patients was performed. As depicted in Figure 4, the median PFS was 139.9 and 
104.5 months (P = .055) and the median OS was 152.3 and 104.5 months (P = .091) for pCR 
and pTisN0M0 patients, respectively.
Discussion
MIUC remains a frequent clinical dilemma with significant treatment-associated morbidity, 
in addition to high relapse rates. The ability to identify patients with MIUC with a greater 
risk of treatment failure, relapse, and decreased survival could have numerous potential 
benefits. These theoretically could include designing future studies of more aggressive 
subsets of patients who might benefit from alternative treatment regimens, evaluating high-
risk tumor profiles for a better understanding of the underlying biology of the disease, and 
detecting potential novel targets for therapy in high-risk patients. Higher primary tumor 
stage and nodal metastases are known risk factors in MIUC that affect survival and are 
reflected in the current staging system; however, these can be difficult to accurately assess 
before definitive therapy, somewhat limiting their usefulness in preoperative treatment 
decisions.3 Additional factors affecting the risk of relapse in patients with MIUC that are not 
considered in the current staging system include primary tumor location at the bladder neck 
or ureterovesical junction (especially with associated hydroureteronephrosis), sarcomatoid, 
small cell, or micropapillary variant histologic features, and an abnormal immunophenotype 
for p53, Rb, or vascular endothelial growth factor.18 The presence of CIS on pre-NAC 
TURBT could be another potential risk-modifying feature in MIUC, because it has been 
shown to have negative prognostic implications in studies of UC, as discussed previously. 
Additionally, if found to be a risk-modifying feature of MIUC, pre-NAC TURBT CIS could 
have clinical utility, because it is an objective finding identifiable by pretreatment pathologic 
examination. Thus, it could potentially guide further treatment decisions for these patients. 
Despite this, the presence of pre-NAC TURBT CIS has received limited evaluation in 
MIUC.
The results of our study revealed significantly decreased pCR rates at cystectomy among 
patients with pre-NAC CIS in their TURBT samples. This finding is noteworthy, because 
pCR is a frequently used early endpoint in clinical trial designs in the NAC setting for 
MIUC. Our results are similar to the results previously reported by Parker et al.21
Interestingly, the survival analysis showed that patients with TURBT CIS had numerically 
greater median PFS and OS outcomes; however, the differences were not statistically 
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significant. This was unexpected, because we hypothesized that TURBT CIS would not only 
result in decreased pCR rates but would also result in decreased PFS and OS. A potential 
explanation for the longer than expected PFS and OS for these patients could be the 
uncontrolled differences in clinical stage between our cohorts, because more patients in the 
TURBT CIS cohort had lower stage (T2) disease and more patients in the non–CIS cohort 
had higher stage (lymph node-positive) disease. In addition, more patients in the TURBT 
CIS cohort received cisplatin-based treatment, which is the only chemotherapy regimen 
shown in prospective studies to improve survival. Finally, as hypothesized, differences in 
survival with residual disease might exist between patients with and without CIS.
In addition to differing pCR rates, subjects with TURBT CIS demonstrated a sixfold 
increase in the rate of pTisN0M0 at cystectomy. In an exploratory post hoc analysis of PFS 
and OS among pCR versus pTisN0M0 patients, those achieving a pCR had numerically 
superior outcomes, although the difference was not statistically significant and PFS and OS 
were prolonged in both subsets. The number of patients analyzed (pCR, n = 26; pTisN0M0, 
n = 11) was extremely small. In their previous analysis, Parker et al21 suggested that 
pTisN0M0 might behave more similarly to a pCR as a potential reason for the lack of a 
significant survival difference seen in their study. To the best of our knowledge, large 
previous efforts have not been performed to assess whether a true clinically significant 
difference exists in the outcomes between patients with pCR versus pTisN0M0 after NAC 
for MIUC. Given the prolonged median PFS and OS in both groups in our study and the lack 
of significant survival outcome differences in the study by Parker et al,21 further prospective 
evaluations of survival outcomes of patients with pCR versus pTisN0M0 are warranted. It is 
difficult to make a definitive conclusions, given the retrospective nature of our study, small 
sample size, and post hoc analysis. However, if pTisN0M0 truly results in prolonged 
survival, this is a critical finding, given that the current standard endpoint in NAC clinical 
trials is the pCR.
Our analysis demonstrated a markedly increased pCR rate in nonwhite patients with MIUC 
treated with NAC. It is plausible that different races might have different tumor biology as 
an explanatory factor. However, caution is warranted in making any definitive conclusions 
from this finding owing to the extremely small number of nonwhite patients treated in our 
cohort.
The strengths of our study included the number of NAC MIUC patients evaluated, the use of 
an objective preoperative variable (ie, the presence vs. absence of TURBT CIS), an objective 
postoperative endpoint (ie, pCR), cystectomy pathology reports assessed by similarly trained 
genitourinary pathologists at a single institution, the high overall rate of cisplatin-based 
regimens received, cystectomies performed by similarly trained urologists at a single 
institution, and the inclusion only of patients who had received NAC. Despite these 
strengths, a number of limitations must be acknowledged. Our study was limited to a single 
institution; thus, the patient outcomes could have been subject to institutional practice 
patterns, which might vary from the patterns of care in other geographic regions of the 
United States. Furthermore, the study was a retrospective evaluation spanning > 2 decades. 
Significant changes in care and management of UC have occurred (eg, an increased use of 
bacillus Calmette-Guérin in NMIUC, the documented benefit of NAC in MIUC, an 
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increased use of extended lymph node dissection), which might have introduced 
unaccounted-for confounding variables affecting the clinical outcomes. Although 
unexpected, the fairly large discrepancy among the clinical stages among our cohorts 
represents another limitation. However, we attempted to control for this on multivariate 
analysis. A potential reason for the presence of more clinically limited stage tumors in the 
TURBT CIS cohort might be related to the knowledge of CIS as a high-risk feature, 
combined with closer surveillance for NMIUC patients, leading to early recognition of 
MIUC in these patients. Another limitation was the inherent sampling error and tumor 
heterogeneity, which can make the identification of TURBT CIS difficult, in addition to the 
less judicious reporting of CIS in the past. Thus, 3 patients were found to have pTisN0M0 at 
cystectomy in the non-CIS cohort, likely representing TURBT CIS that was not sampled on 
the initial biopsy or pathologic assessment. If the finding of CIS is truly prognostic or 
predictive, a more thorough and standardized evaluation of TURBT specimens and the use 
of improved techniques of identifying CIS would be advisable. Two such techniques include 
blue light and narrow band cystoscopy, both of which have been shown to improve the 
detection of CIS in NMIUC compared with traditional white light cystoscopy.22–25 Finally, 
our survival analyses were limited by the variable follow-up durations and considerable 
number of patients censored with an unknown event status.
Conclusion
Our study identified a significant association between the presence of CIS within the 
pretreatment TURBT sample of MIUC patients treated with NAC and decreased pCR rates 
at cystectomy. An analysis of survival outcomes, albeit limited by the small retrospective 
sample sizes, did not show an associated decrease in survival outcomes in association with 
TURBT CIS histologic features. Furthermore, the finding of pTisN0M0 at cystectomy is 
common in patients with CIS found on pre-NAC TURBT samples. The clinical consequence 
of this finding remains undefined, although our data suggest the survival outcomes for these 
patients might be prolonged. Further delineation of any significant difference between 
pTisN0M0 and pCR outcomes will likely require prospective validation through large 
international data registries. Further study of patients with CIS could offer opportunities for 
improved translational study, which might have important clinical ramifications for both 
NMIUC and MIUC patients.
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Clinical Practice Points
• CIS in isolation or when identified with invasive urothelial cancer has been 
shown in multiple studies to have poor prognostic implications.
• CIS identified in pretreatment biopsy samples of patients treated with NAC 
results in decreased pCR rates at cystectomy; however, no significant 
differences in median PFS or OS were found.
• Among patients with CIS found on pretreatment biopsies, significant 
proportions of cystectomy samples revealed CIS only after NAC.
• Residual CIS at cystectomy resulted in prolonged median PFS and OS that 
were not significantly different from the median PFS and OS found with a 
pCR.
• Judicious evaluation and reporting of associated CIS should be performed to 
further understand the prevalence and prognostic significance of this finding.
• Further studies with the aim of understanding the underlying biology of CIS, 
given its differing clinical behavior, are warranted.
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Figure 1. Schema
Abbreviations: CIS = carcinoma in situ; MIUC = muscle-invasive urothelial carcinoma; pCR 
= pathologic complete response; TURBT = transurethral resection of bladder tumor.
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Figure 2. Analysis Cohort Selection
Abbreviations: NAC = neoadjuvant chemotherapy; NE = neuroendocrine; Pts = patients.
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Figure 3. Survival According to Transurethral Resection of Bladder Tumor (TURBT) 
Carcinoma In Situ (CIS) Status. (A) Progression-free Survival (PFS). (B) Overall Survival (OS)
Abbreviation: CI = confidence interval.
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Figure 4. Survival According to Pathologic Complete Response (pCR) Versus pTisN0M0 Status. 
(A) Progression-free Survival (PFS). (B) Overall Survival (OS)
Abbreviation: CI = confidence interval.
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Table 1
Patient Demographics
Variable Full Cohort (n = 137) CIS TURBT (n = 42) No CIS TURBT (n = 95) P Value
Age (y) 61.1 ± 11.0 61.5 ± 10.4 60.9 ± 11.2 .94
Creatinine (mg/dL) 1.2 ± 0.4 1.1 ± 0.4 1.2 ± 0.4 .55
WBC count (K/mL) 7.5 ± 2.4 7.4 ± 2.5 7.6 ± 2.4 .74
Hemoglobin (g/dL) 13.0 ± 2.2 13.1 ± 2.3 12.9 ± 2.2 .68
Platelet count (K/mL) 273.2 ± 99.4 278.7 ± 143.4 271.4 ± 80.3 .76
CIS on TURBT 42 (30.7) NA NA NA
Variant histologic features 46 (33.6) 16 (38.1) 30 (31.6) .46
ECOG PS .20
 0 25 (18.2) 6 (14.3) 19 (20.0)
 1 27 (19.7) 6 (14.3) 21 (22.1)
 2 5 (3.6) 3 (7.1) 2 (2.1)
 Unknown 80 (58.4) 27 (64.3) 53 (55.8)
White race 128 (93.4) 40 (95.2) 88 (92.6) .57
Male gender 104 (75.9) 29 (69.0) 75 (78.9) .21
Clinical stage
 T2N0 83 (60.6) 30 (71.4) 53 (55.8) .08
 T3-T4N0 14 (10.2) 4 (9.5) 10 (10.5) .86
 Any T, N+ 40 (29.2) 8 (19.0) 32 (33.7) .08
Cisplatin-containing regimen 113 (82.5) 38 (90.5) 75 (78.9) .10
Data presented as mean ± standard deviation or n (%).
Abbreviations: CIS = carcinoma in situ; ECOG = Eastern Cooperative Oncology Group; PS = performance status; TURBT = transurethral resection 
of bladder tumor; WBC = white blood cell.
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Table 2
Tumor Response at Cystectomy
Outcome CIS TURBT (n = 42) No CIS TURBT (n = 95) P Value
Complete response (pCR) 4 (9.5) 22 (23.2) .07
Pathologic TisN0M0 8 (19.0) 3 (3.2) <.01
Pathologic <T2N0M0 18 (42.9) 35 (36.8) .51
Pathologic N+M0 14 (33.3) 25 (26.3) .40
Pathologic M1 0 (0.0) 2 (2.1) 1.00
Abbreviations: CIS = carcinoma in situ; pCR = pathologic complete response; TURBT = transurethral resection of bladder tumor.
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